The 2018 Farm Bill Created an Unregulated Market for Potent Synthetic Cannabinoids Made From CBD

The CBD-derived cannabinoid market has expanded from delta-8-THC to include potent synthetic cannabinoids with greater agonist activity at CB1 receptors than delta-9-THC. The acetate ester motif (linked to EVALI vaping lung injuries) has been incorporated into multiple THC analogues. Products contain under-researched reaction side products from manufacturing. Regulatory oversight is virtually nonexistent.

Narrative review summarizing current scientific knowledge on psychoactive cannabinoids synthesized from CBD, including delta-8-THC, O-acetyl-THC, and novel sidechain variants. Reviews manufacturing processes, regulatory gaps, epidemiological findings, and pharmacological concerns.

Millions of Americans are consuming CBD-derived cannabinoids that may be more potent than THC, contain unknown reaction byproducts, and include chemical structures linked to serious lung injuries. This represents a regulatory blind spot created by the Farm Bill's hemp legalization that could become a public health crisis.

The trajectory mirrors previous substance crises. Like bath salts and synthetic cannabinoids (K2/Spice) before them, CBD-derived products exploit regulatory gaps to sell psychoactive substances as "legal" alternatives. The key difference is scale: CBD-derived cannabinoids are sold in mainstream retail settings to consumers who may not realize they are using untested synthetic drugs.

The review relies on limited available research, as most CBD-derived cannabinoids have never been formally studied. Market composition changes rapidly, potentially outpacing the review. The actual prevalence of adverse events may be substantially underreported.